(IN BRIEF) Novartis has announced promising 96-week results from the Phase III ASC4FIRST trial, showcasing Scemblix® (asciminib) as a superior treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP). Scemblix achieved significantly higher major … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged 96-week results, asciminib, ASH Annual Meeting, chronic myeloid leukemia, CML care, discontinuation rate, imatinib, major molecular response, MMR, National Comprehensive Cancer Network, NCCN, newly diagnosed settings, Novartis, oncology, Ph+ CML-CP, Phase II ASC2ESCALATE trial, Phase III ASC4FIRST trial, Philadelphia chromosome-positive chronic myeloid leukemia, safety, Scemblix, Second-Line Treatment, severe adverse events, standard-of-care, TKIs, tolerability, tyrosine kinase inhibitors
(IN BRIEF) AstraZeneca’s Imfinzi (durvalumab) has been granted Priority Review by the FDA for the treatment of muscle-invasive bladder cancer (MIBC), potentially becoming the first perioperative immunotherapy in this curative-intent setting. Supported by results from the NIAGARA Phase III trial, … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AstraZeneca, bladder cancer, FDA, Imfinzi, Perioperative Immunotherapy, safety, Susan Galbraith
(IN BRIEF) Eckert & Ziegler and Ariceum Therapeutics have signed a global supply agreement for critical medical radionuclides Actinium-225 (Ac-225) and Lutetium-177 (Lu-177). The radionuclides will be used in Ariceum’s lead radiopharmaceutical drug, satoreotide, targeting hard-to-treat cancers such as small … Read the full press release
Posted in Business, Environment, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Ariceum Therapeutics, Critical Medical Radionuclides, Dr. Harald Hasselmann, Eckert & Ziegler, Healthcare, Manfred Rüdiger, partnership, sustainability
(IN BRIEF) Boehringer Ingelheim has launched EURICAN® L4, a new vaccine designed to protect dogs from leptospirosis, a potentially fatal disease spread through contaminated soil and water. Available in France and expanding across Europe in 2025, the vaccine targets four … Read the full press release
(IN BRIEF) QIAGEN is investing in a new innovation hub in Esplugues de Llobregat, Barcelona, to enhance its QIAstat-Dx syndromic testing platform. Opening in 2026, the 8,000-square-meter site will house operations across research, manufacturing, and regulatory functions, focusing on advancing … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, Netherlands, News, Pharma & Biotech, Science, Spain, Technology
Tagged Barcelona, Innovation Hub, partnership, QIAGEN, QIAstat-Dx Operations, sustainability, Thierry Bernard
(IN BRIEF) The European Commission has approved Theralugand®, Eckert & Ziegler’s high-purity Lutetium-177 chloride, for routine clinical use across the European Economic Area. This approval allows its application in targeted cancer therapies, such as for neuroendocrine tumors and metastatic prostate … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Cancer Therapies, Dr. Harald Hasselmann, Eckert & Ziegler, EU, Healthcare, safety, Theralugand®, wellness
(IN BRIEF) Boehringer Ingelheim has launched VETMEDIN® Solution, the first FDA-approved liquid treatment for congestive heart failure (CHF) in dogs caused by myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM). The solution provides a convenient, twice-daily alternative to tablets, … Read the full press release
(IN BRIEF) Novartis has secured European Commission approval for Kisqali® (ribociclib) in combination with endocrine therapy (ET) as an adjuvant treatment for high-risk hormone receptor-positive (HR+), HER2-negative early breast cancer (EBC). The approval, based on the Phase III NATALEE trial, … Read the full press release
(IN BRIEF) Roche has announced the acquisition of Poseida Therapeutics, a clinical-stage biopharmaceutical company specializing in off-the-shelf CAR-T cell therapies, for $9.00 per share in cash, totaling approximately $1 billion. Poseida stockholders may also receive up to $4.00 per share … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged acquisition, Aviv Regev, cell therapy, INNOVATION, Levi Garraway, partnership, Poseida Therapeutics, Roche, sustainability, USA
(IN BRIEF) Roche provided an update on its Phase III SKYSCRAPER-01 study, evaluating tiragolumab in combination with Tecentriq® for patients with PD-L1-high, advanced, or metastatic non-small cell lung cancer (NSCLC). The study did not meet its primary endpoint of improving … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Lung Cancer Therapy, Roche, safety, SKYSCRAPER-01 Study, TECENTRIQ, Tiragolumab
(IN BRIEF) Vodafone Business IoT and Controlant are transforming the pharmaceutical supply chain by providing real-time monitoring for temperature-sensitive medicines. Controlant’s Saga devices, equipped with Vodafone IoT SIMs, ensure reliable global connectivity, reducing waste and carbon emissions. This solution has … Read the full press release
Posted in Business, Environment, Financial, Government, Industrial, Internet & Online, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Controlant, Gísli Herjólfsson, partnership, Pharmaceutical Supply Chain, Real-time monitoring, sustainability, vodafone, Vodafone Business IoT
(IN BRIEF) Fresenius Kabi is addressing the global threat of antimicrobial resistance (AMR), which causes millions of deaths annually, through sustainable manufacturing, improved antibiotic access, and promoting responsible use. During AMR Awareness Week, the company highlighted its commitment to reducing … Read the full press release
(IN BRIEF) Research published in the European Heart Journal reveals that combining anticoagulants with NSAIDs, such as ibuprofen, diclofenac, or naproxen, significantly increases the risk of internal bleeding. The study, involving over 51,000 patients in Denmark, found that the bleeding … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Anticoagulants, diclofenac, Elevated Bleeding, ESC, Healthcare, ibuprofen, naproxen, NSAIDs, Professor Robert F. Storey, rivaroxaban, Søren Riis Petersen, warfarin
(IN BRIEF) AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the EU for treating adult patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) with EGFR mutations who have not experienced disease progression after platinum-based chemoradiation therapy. This … Read the full press release
Posted in Business, European Union, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Adrian Kemp, AstraZeneca, Dr. Manuel Cobo, safety, Susan Galbraith, Tagrisso, therapy, Unresectable EGFR-Mutated Lung Cancer
(IN BRIEF) In his doctoral research at the University of Helsinki, Matej Zore demonstrated the potential of repurposing the drugs fingolimod and etrasimod, originally developed for autoimmune diseases, to combat antimicrobial resistance (AMR). These drugs showed notable efficacy against drug-resistant … Read the full press release
Posted in Business, Education, Financial, Finland, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged antimicrobial resistance, etrasimod, fingolimod, Matej Zore, methicillin-resistant Staphylococcus aureus (MRSA), Professor Fredrik Almqvist, Professor Jari Yli-Kauhaluoma, Repurposing Drugs, University of Helsinki, vancomycin-resistant Enterococcus (VRE)
(IN BRIEF) Henkel and Linxens are collaborating to advance printed electronics for medical wearables, debuting a skin patch concept featuring self-regulating heating elements designed to enhance patient comfort. The innovation, ideal for applications like pain relief and temperature-regulated drug delivery, … Read the full press release
Posted in Chemicals, Germany, Healthcare, Pharma & Biotech
Tagged biosensors, carbon resistive inks, conductive inks, connectivity, flexible circuits, Healthcare, Henkel, INNOVATION, IoT, Linxens, Linxens Healthcare, Loctite portfolio, MEDICA trade show, medical wearables, Minh Lê, pain relief, patient comfort, Pia Schmiedel, Positive Temperature Coefficient inks, printed electronics, resistive inks, Roll-to-Roll screen printing, self-regulating heating elements, silver conductive inks, skin patches, temperature-controlled drug delivery
(IN BRIEF) A Phase III trial of Tezspire (tezepelumab) by AstraZeneca and Amgen has shown significant benefits for patients with chronic rhinosinusitis with nasal polyps (CRSwNP), reducing both nasal polyp size and congestion compared to a placebo. The WAYPOINT trial … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Adrian Kemp, Amgen, AstraZeneca, chronic rhinosinusitis, Dr. Brian Lipworth, Dr. Joseph Han, Healthcare, Nasal Polyp Symptoms, partnership, safety, Sharon Barr, sustainability, tezepelumab, Tezspire, USA
(IN BRIEF) Logicor has extended its lease with DHL Poland at its Mysłowice logistics park, where DHL occupies 12,200 sqm of warehouse space and provides logistical support for Bausch Health Poland. The facility, tailored for pharmaceutical needs with advanced temperature … Read the full press release
Posted in Business, Environment, Financial, Government, Industrial, Infrastructure & Utilities, Investment, Management, News, Pharma & Biotech, Poland, Real Estate, Technology, Transportation & Logistics, United Kingdom
Tagged DHL Poland, Logicor, Mysłowice, partnership, Pharmaceutical Logistics Hub, Piotr Brycki, sustainability
(IN BRIEF) The European Medicines Agency has approved Dupixent as the first treatment for eosinophilic esophagitis (EoE) in young children aged one to 11, marking a significant step in managing this condition in a critical developmental phase. The approval is … Read the full press release
Posted in Business, Education, European Union, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Dr. George Yancopoulos, Dr. Houman Ashrafian, Dupixent, eosinophilic esophagitis, EU, European Medicines Agency (EMA), Healthcare, Regeneron, safety, Sanofi, treatment, wellness, Young Children
(IN BRIEF) SGS has introduced advanced laser diffraction technology at its Wavre, Belgium lab, enhancing its ability to measure droplet sizes in spray drug delivery systems. This investment in Malvern Spraytec technology allows for real-time data collection during the spray … Read the full press release
Posted in Belgium, Business, Environment, Financial, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Belgium, investment, Laser Diffraction Technology, Malvern Spraytec laser diffraction system, partnership, Pharmaceutical Spray Testing, safety, SGS, sustainability
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?